Common questions about BSS Plus 250 mL (FAQ)
Q: Is BSS Plus 250 mL considered a medicine, a saline solution, or a medical device?
According to official regulatory documents, BSS Plus is classified as a Human Prescription Drug product, specifically designated as an Ophthalmic Irrigating Solution. It is noted that it has no pharmacological action, meaning it does not contain substances designed to treat illness like traditional medicine.
Q: Do patients commonly experience blurry vision or eye irritation after BSS Plus is used?
Ocular discomfort has been reported as a potential adverse reaction in clinical studies. While blurry vision is not specifically listed as a common reaction to the solution itself, regulatory guidance indicates that patients should seek immediate care for any problems with their vision following the surgical procedure.
Q: Can BSS Plus affect the lens or cornea during a procedure?
The solution is specifically designed to help maintain the integrity of the cornea during surgery. However, official warnings advise that it should be used with caution in patients who have diabetes and are undergoing a specific type of surgery called a vitrectomy, due to observations of potential intraoperative lens changes noted with similar solutions.
Q: Is it possible to have an allergic reaction to the components in BSS Plus?
Official documentation does not list allergic reactions as a specific adverse event directly linked to BSS Plus. As a general precaution, regulatory guidance indicates that individuals should seek medical attention for any potential signs of a severe allergic reaction (such as swelling of the face or hives) following the surgical procedure.
Q: If a patient is pregnant or breastfeeding, does BSS Plus pose a risk?
The official prescribing information for BSS Plus explicitly states that there is no specific data or classification provided regarding its safety status or eligibility for use in pregnant or breastfeeding individuals.
Q: Does the use of BSS Plus require special consideration for children?
Regulatory documents indicate that no overall differences in safety or effectiveness have been observed when comparing its use in pediatric patients (children and adolescents) to its use in adults.
Q: Is corneal edema reported as an occasional adverse reaction with BSS Plus?
Corneal edema (swelling of the cornea) has been reported as a post-operative event in regulatory documents. However, official documentation notes that a definitive causal relationship to the use of BSS Plus has not been established by the regulator.
Q: Is BSS Plus used in procedures other than those involving the eye?
The product is explicitly labeled 'For IRRIGATION during ophthalmic surgery only'. Its regulated use is strictly restricted to being administered within the eye during surgical procedures.
Q: What happens if the vacuum seal on the BSS Plus bottle is broken before use?
Regulatory guidelines state that the solution must not be used if the container is damaged, or if the seal is not intact or a vacuum is not present. This is a required precaution to ensure the solution's sterility and integrity before use.
Q: What kind of post-operative issues have been reported after the use of BSS Plus?
Reported post-operative issues mentioned in regulatory documentation include inflammatory reactions, corneal edema, and corneal decompensation. It is important to note that the regulatory documentation states the causal relationship between these issues and the solution has not been established.
Q: Is BSS Plus a type of antibiotic or painkiller?
No. The solution is specifically noted to have no pharmacological action in the body. Its sole purpose is to serve as a supportive irrigating fluid during surgical procedures, not to treat bacterial infections or relieve pain.
Q: Is BSS Plus the same as the saline solution I use for my contact lenses?
BSS Plus is a highly specialized, multi-ionic irrigating solution used only within the eye during surgical procedures. Its complex composition, which includes vital electrolytes and an energy source, is regulated for use as a surgical aid and is distinct from standard saline solutions typically used for contact lenses.
Q: Is it normal to have a mild headache after a procedure involving BSS Plus?
Headache is listed in regulatory documentation as a potential adverse reaction that was observed in clinical studies. The regulator only reports the frequency of the event and does not define the 'normalcy' or expected duration of post-operative symptoms.
Q: What is the significance of the 250 mL volume of the product?
The 250 mL volume refers to the Part I component of the two-part solution that must be mixed prior to use in surgery. The actual volume of the solution used on a patient is not fixed and is determined by the operating surgeon's standard technique and the needs of the procedure.
Q: Does BSS Plus contain any preservatives?
Official regulatory warnings explicitly state that BSS Plus does not contain a preservative. This lack of preservatives is why the solution has a strict six-hour time limit after mixing before it must be discarded.
Q: Is BSS Plus intended to relieve pain during or after surgery?
No. The solution is described in regulatory documents as having no pharmacological action. Its purpose is to maintain tissue viability and integrity inside the eye during surgery, not to relieve pain.
Q: Why does the solution need to be clear and free of precipitate before use?
Regulatory warnings mandate that the solution must not be used if it is discolored or contains a precipitate. This is a crucial safety instruction because the presence of unauthorized substances could lead to tissue damage if introduced into the eye, which is a key safety precaution.
Q: Is BSS Plus a high-osmolality or low-osmolality solution?
The osmolality of the fully reconstituted solution is stated in the description as approximately 305 mOsm. This measurement is provided to indicate that the solution is formulated to maintain a suitable physiological environment for the delicate tissues of the eye.
